<a href="https://www.fiercebiotech.com/biotech/lilly-pens-12b-deal-hanmis-glp-2-drug-being-aimed-short-bowel-syndrome" hreflang="en">Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome</a>
Eli Lilly has signed a $1.2 billion deal to license Hanmi Pharmaceutical's GLP-2 drug, sonefpeglutide, which is in mid-stage trials for treating short bowel syndrome. The agreement includes an upfront payment of $75 million and potential milestone payments, as Lilly aims to expand its gastrointestinal portfolio.
Eli Lilly's $1.2 billion licensing deal with Hanmi Pharmaceutical for the GLP-2 agonist sonefpeglutide, aimed at treating short bowel syndrome, highlights a significant investment opportunity in rare disease therapeutics. This move positions Lilly to potentially disrupt the market dominated by Takeda's Gattex by offering a long-acting monthly treatment alternative, which could reduce treatment burdens for patients. This indicates a strategic focus on expanding into niche gastrointestinal indications, leveraging innovative delivery platforms like Hanmi's Lapscovery.